Nautilus Biotechnology, Inc. (NAUT)
NAUT · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Signal Snapshot
0
Clinical Trials (ClinicalTrials.gov aggregate)
0
Catalyst Records
2
Publications on Record
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- Responsive stimulation of the thalamus for idiopathic generalized epilepsy: Results of the randomized controlled NAUTILUS trial through 18 months. — Epilepsia (2026) PMID 42233958
- Clinicopathologic characteristics and lymph node status in the NAUTILUS clinical trial:KBCSG-21. — Eur J Surg Oncol (2026) PMID 41689946
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Nautilus Biotechnology, Inc..
Full NAUT Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.